Sio Capital Management, LLC
- SEC CIK
- 0001482416
- Latest filing
- Aug 14, 2026
Holdings in Q1 2023
Holdings as of Mar 31, 2023, filed May 12, 2023. Long positions only; changes compare share counts with Q4 2022.
- Positions
- 44
- +3 vs. Q4 2022
- Portfolio value
- $202.3M
- +$14.7M (+7.8%) vs. Q4 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| CNCCentene Corp | Stock | 432,834 | $27.4M | 13.5% | +432,834 | New | History |
| CICigna Group | Stock | 87,175 | $22.3M | 11.0% | +34,564+65.7% | Added | History |
| BCYCBicycle Therapeutics PLC | SPONSORED ADS | 967,347 | $20.6M | 10.2% | +283,922+41.5% | Added | History |
| CORCencora, Inc. | Stock | 128,164 | $20.5M | 10.1% | +43,765+51.9% | Added | History |
| UTHRUnited Therapeutics Corp | COM | 75,003 | $16.8M | 8.3% | +20,044+36.5% | Added | History |
| GEHCGE HealthCare Technologies Inc. | Stock | 196,887 | $16.2M | 8.0% | +196,887 | New | History |
| OGNOrganon & Co. | Stock | 471,553 | $11.1M | 5.5% | −116,283−19.8% | Reduced | History |
| MDTMedtronic plc | Stock | 84,012 | $6.77M | 3.3% | −43,988−34.4% | Reduced | History |
| AVTRAvantor, Inc. | COM | 283,136 | $5.99M | 3.0% | +33,136+13.3% | Added | History |
| ADCTADC Therapeutics SA | SHS | 2,160,632 | $4.21M | 2.1% | +2,160,632 | New | History |
| VKTXViking Therapeutics, Inc. | COM | 250,000 | $4.16M | 2.1% | +250,000 | New | History |
| AXNXAxonics, Inc. | COM | 70,841 | $3.87M | 1.9% | +70,841 | New | History |
| GMEDGlobus Medical Inc | Stock | 67,500 | $3.82M | 1.9% | +67,500 | New | History |
| RLAYRelay Therapeutics, Inc. | COM | 230,013 | $3.79M | 1.9% | +230,013 | New | History |
| MACKMerrimack Pharmaceuticals Inc | COM NEW | 272,843 | $3.35M | 1.7% | +22,843+9.1% | Added | History |
| RVMDRevolution Medicines, Inc. | COM | 125,957 | $2.73M | 1.3% | +125,957 | New | History |
| Eucrates Biomedical Acqu CorG3141W114 | UNIT 10/23/2027 | 248,674 | $2.58M | 1.3% | 00.0% | Unchanged | – |
| RPTXRepare Therapeutics Inc. | COM | 228,538 | $2.25M | 1.1% | +228,538 | New | History |
| CTICCti Biopharma Corp | COM | 526,239 | $2.21M | 1.1% | +196,239+59.5% | Added | History |
| SVRASavara Inc | COM | 948,457 | $1.85M | 0.9% | +82,009+9.5% | Added | History |
| PHVSPharvaris N.V. | COM | 228,385 | $1.84M | 0.9% | −56,615−19.9% | Reduced | History |
| HSKAHeska Corp | COM RESTRC NEW | 17,450 | $1.70M | 0.8% | −66,859−79.3% | Reduced | History |
| ELEVElevation Acquisition Group Inc. | COM | 876,611 | $1.67M | 0.8% | +516,880+143.7% | Added | History |
| INGNInogen Inc | COM | 121,535 | $1.52M | 0.7% | −165,157−57.6% | Reduced | History |
| NYXHNyxoah SA | COMMONSTOCK | 188,875 | $1.41M | 0.7% | +172,765+1,072.4% | Added | History |
| CNTACentessa Pharmaceuticals plc | SPONSORED ADS | 347,869 | $1.34M | 0.7% | +347,869 | New | History |
| APREAprea Therapeutics, Inc. | COM NEW | 280,000 | $1.24M | 0.6% | +280,000 | New | History |
| CRBPCorbus Pharmaceuticals Holdings, Inc. | COM NEW | 150,000 | $1.09M | 0.5% | +150,000 | New | History |
| MODDModular Medical, Inc. | COM NEW | 689,352 | $999.6K | 0.5% | 00.0% | Unchanged | History |
| MBRXMoleculin Biotech, Inc. | COM | 1,010,956 | $970.5K | 0.5% | −25,897−2.5% | Reduced | History |
| IDYAIDEAYA Biosciences, Inc. | COM | 70,000 | $961.1K | 0.5% | 00.0% | Unchanged | History |
| FUSNFusion Pharmaceuticals Inc. | COM | 246,036 | $927.6K | 0.5% | −14,412−5.5% | Reduced | History |
| SYRESpyre Therapeutics, Inc. | COM | 3,004,959 | $871.4K | 0.4% | 00.0% | Unchanged | History |
| VNDAVanda Pharmaceuticals Inc. | COM | 123,797 | $840.6K | 0.4% | −12,528−9.2% | Reduced | History |
| Aslan Pharmaceuticals Ltd04522R200 | SPON ADS NEW | 254,150 | $732.0K | 0.4% | +254,150 | New | – |
| Neovasc Inc64065J403 | Equity | 22,537 | $657.0K | 0.3% | +22,537 | New | – |
| SIENProject Sage Oldco, Inc. | COM | 254,997 | $392.7K | 0.2% | 00.0% | UnchangedConverted for a 1-for-10 split | History |
| MRUSMerus N.V. | COM | 15,564 | $286.4K | 0.1% | −72,389−82.3% | Reduced | History |
| NXTCNextCure, Inc. | COM | 130,000 | $192.4K | 0.1% | 00.0% | Unchanged | History |
| VINCVincerx Pharma, Inc. | COM NEW | 102,049 | $106.1K | 0.1% | 00.0% | Unchanged | History |
| CMAXCareMax, Inc. | COM CL A | 30,741 | $82.1K | <0.1% | −12,808−29.4% | Reduced | History |
| Rocket Pharmaceuticals, Inc.77313F114 | *W EXP 09/02/202 | 400,000 | $65.4K | <0.1% | +400,000 | New | – |
| Humacyte, Inc.44486Q111 | *W EXP 09/21/202 | 49,998 | $29.9K | <0.1% | +49,998 | New | – |
| CareMax, Inc.14171W111 | *W EXP 06/08/202 | 12,808 | $5.67K | <0.1% | +12,808 | New | – |
Sold out since Q4 2022 (14)
Positions held at the end of Q4 2022 that are gone from this filing.
| Security | Class | Shares in Q4 2022 | Value in Q4 2022 | % of portfolio in Q4 2022 | History |
|---|---|---|---|---|---|
| Medicus Sciences AcquisitionG5960S108 | CL A SHS | 2,323,000 | $23.4M | 12.5% | – |
| STAAStaar Surgical Co | COM PAR $0.01 | 157,129 | $7.63M | 4.1% | History |
| ICLRIcon PLC | COM | 33,983 | $6.60M | 3.5% | History |
| PTGXProtagonist Therapeutics, Inc | COM | 434,635 | $4.74M | 2.5% | History |
| NVAXNovavax Inc | COM NEW | 340,000 | $3.50M | 1.9% | History |
| CBAYCymaBay Therapeutics, Inc. | COM | 555,610 | $3.48M | 1.9% | History |
| OBIOOrchestra BioMed Holdings, Inc. | ORD SHS | 250,000 | $2.50M | 1.3% | History |
| XFORX4 Pharmaceuticals, Inc | COM | 1,825,963 | $1.81M | 1.0% | History |
| TYRATyra Biosciences, Inc. | COM | 152,159 | $1.16M | 0.6% | History |
| RLMDRelmada Therapeutics, Inc. | COM | 235,500 | $821.9K | 0.4% | History |
| CNTBConnect Biopharma Holdings Ltd | ADS | 597,678 | $518.7K | 0.3% | History |
| Aslan Pharmaceuticals Ltd04522R101 | ADS | 1,270,758 | $457.5K | 0.2% | – |
| HUMAHumacyte, Inc. | COM | 49,998 | $20.3K | <0.1% | History |
| NGNENeurogene Inc. | COM | 38,312 | $19.5K | <0.1% | History |